Wird geladen...
2489. Adverse Events with Biktarvy: Post-Marketing Study
BACKGROUND: Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) was FDA approved in February 2018. There are no published post-marketing data evaluating safety and efficacy. After large uptake of BIC/FTC/TAF at our institution, reports of rash prompted a real-world review. The purpose...
Gespeichert in:
| Veröffentlicht in: | Open Forum Infect Dis |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Oxford University Press
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6810394/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.2167 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|